Adverum Biotechnologies Profit Margin

The latest profit margin for ADVM is 4909.64% as of September 2025. That compares with 3619.65% in the prior-year period — up 35.6% year over year. That is above the Healthcare sector average of 21.34%. Investors often review this figure alongside Adverum Biotechnologies's historical trend and sector peers before judging valuation or financial health.

Over the past year, ADVM's profit margin moved from 3619.65% to 4909.64% — a 35.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Adverum Biotechnologies's valuation or profitability profile.

Against Healthcare companies, ADVM currently prints 4909.64% for profit margin, while the sector average sits near 21.34%. That is roughly 22911.9% above the sector mean. Large gaps often invite a closer look at Adverum Biotechnologies's growth, margins, and balance sheet.

Profit Margin shows how effectively Adverum Biotechnologies converts resources into returns. At 4909.64%, ADVM may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 3619.65% in the prior-year period — up 35.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ADVM's profit margin (4909.64%), review year-over-year change from 3619.65%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.